Drug Search Results
More Filters [+]

HRS-1167

Alternative Names: HRS-1167, HRS 1167, HRS1167, M9466, M-9466
Latest Update: 2025-01-28
Latest Update Note: Clinical Trial Update

Product Description

HRS-1167 is a drug candidate from Jiangsu HengRui Medicine for the treatment of Advanced Solid Tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05473624?term=HRS-1167&draw=2&rank=1)

Mechanisms of Action: PARP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hengrui Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HRS-1167

Countries in Clinic: Australia, Canada, China, Germany, Japan, Korea, Spain, United Kingdom, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Ovarian Cancer|Prostate Cancer

Phase 1: Colorectal Cancer|Healthy Volunteers|Oncology Solid Tumor Unspecified|Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2031240640

P1

Recruiting

Small Cell Lung Cancer

2027-10-06

DDRiver 521

P1

Not yet recruiting

Small Cell Lung Cancer

2027-10-06

jRCT2031240418

P1

Recruiting

Colorectal Cancer

2026-04-07

DDRiver 511

P1

Recruiting

Colorectal Cancer

2026-04-07

Recent News Events